INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma in the United States and Europe and is an aggressive lymphoma with an expected survival of less than 1 year if untreated. 1, 2 However, a significant number of patients are potentially cured with the current standard-of-care rituximab (anti-CD20 monoclonal antibody) plus anthracycline-basedchemotherapy(immunochemotherapy), most commonly given as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). [3] [4] [5] [6] Although the majority of patients treated with immunochemotherapy respond to treatment, 20% to 40% of patients will either fail to achieve remission or they will relapse. Most relapses occur within the first 12 to 18 months, and outcome for these patients is generally poor with salvage therapies, including platinum-based chemotherapy and stem-cell transplantations, resulting in long-term survival in only a minority of patients. [7] [8] [9] [10] Although late relapses may occur, they
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are infrequent, with a recent report identifying only 7% of first relapses occurring more than 5 years after diagnosis in the immunochemotherapy era. 8 Traditionally, clinical studies of DLBCL have used progression-free survival and/or overall survival (OS) as outcomes. However, the event rate slows significantly approximately 12 months after diagnosis, and incorporation of late events can be complicated by competing risks, especially in older patients with comorbid health conditions.
On the basis of these clinical observations, we examined the type and timing of events and evaluated OS and cause-specific survival conditional on being alive and disease-free at 12 and 24 months from diagnosis in patients with DLBCL who were treated with immunochemotherapy. Given the competing risk of death in this generally older population (median age at diagnosis, 60 years), we also compared the OS rate to that expected from the general population, accounting for age and sex. We replicated our main results in independent studies from France. Finally, we assessed the impact of using event-free survival status at 24 months from diagnosis (EFS24) as a primary end point for the design of future treatment trials of DLBCL.
PATIENTS AND METHODS
This study was reviewed and approved by the human subjects institutional review board at the Mayo Clinic and the University of Iowa, and written informed consent was obtained from all participants. Patients were prospectively enrolled onto the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE) [11] [12] [13] or enrolled onto North Central Cancer Treatment Group NCCTG-N0489.
14 The MER cohort consisted of all patients with newly diagnosed DLBCL who received rituximab and anthracycline-based chemotherapy as their initial therapy. All diagnoses were confirmed by a study hematopathologist. Patients with primary mediastinal lymphoma were included; however, patients with primary CNS lymphoma, post-transplantation lymphoproliferative disorder, transformation of a previously diagnosed lymphoma, or DLBCL in association with HIV infection were excluded. Baseline clinical, laboratory, and treatment data were abstracted from medical records by using a standard protocol (MER) or per clinical trial protocol (NCCTG-N0489 [NCT00301821] ). Loss to follow-up was low, since all patients were systematically contacted every 6 months for the first 3 years and then annually (MER) [11] [12] [13] or per clinical trial protocol (NCCTG-N0489). 14 Disease progression or relapse, re-treatment, and death were verified through review of pathology and medical records. Unplanned consolidative radiation therapy, but not radiation therapy as part of the initial treatment plan, was considered a re-treatment. Cause of death was determined by review of death certificates and medical records by using a standard definition developed for Eastern Cooperative Oncology Group ECOG-E4494. 4 Death as a result of disease included progressive/refractory disease not responding to treatment irrespective of other causes of death, cardiac deaths attributable to anthracycline toxicity, and deaths secondary to infections for patients actively receiving chemotherapy. Death unrelated to lymphoma included deaths that were considered independent of malignant lymphoma or chemotherapy treatments (eg, stroke, suicide, accidents).
Replication Study
Data for replication were obtained from an external set of patients with DLBCL who were treated with immunochemotherapy from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Lymphome Non Hodgkinien 2003B (LNH2003B) program [15] [16] [17] [18] [19] and hospital-based registry in Lyon, France. The LNH2003B program of the GELA consisted of six prospective multicenter studies of patients with DLBCL older than age 18 years. Patients were stratified on age and age-adjusted International Prognosis Index for treatment allocation in four randomized phase III and two phase II studies (details in the Data Supplement). All patients had a pathology review confirming the DLBCL diagnosis. In this GELA program, during the first 2 years after treatment, assessment consisted of physical examination and laboratory tests every 3 months and computed tomography scans of the chest, abdomen, and pelvis every 6 months. Thereafter, physical examination and laboratory tests were done every 6 months and computed tomography scans every year for 5 years. The Lyon registry consisted of all patients with newly diagnosed DLBCLs treated with immunochemotherapy in routine clinical practice at the Léon Bérard Cancer Center between August 1998 and December 2008 and observed through 2010. Further details on these studies are in the Data Supplement.
Statistical Methodology
OS was defined as time from diagnosis until death as a result of any cause; cause-specific survival was summarized using common causes of death. Event-free survival (EFS) was defined as time from diagnosis until relapse or progression,unplannedre-treatmentoflymphomaafterinitialimmunochemotherapy, or death as a result of any cause. EFS indicators at predefined cut points (ie, EFS at 12 months [EFS12] or EFS at 24 months [EFS24]) were defined on the basis of EFS status at the indicated cut point after date of diagnosis. Kaplan-Meier curves were used to display survival curves. Event decomposition was performed by using a competing risk approach.
20 Expected survival accounting for age and sex was generated in R by using the general US (survexp.us) 21 and French (survexp.fr) 22 populations as reference groups for the US and French studies, respectively. [22] [23] [24] Observed versus expected OS was plotted by using a conditional approach 25 and summarized by using standardized mortality ratios (SMRs) of observed to expected deaths.
26
Simulation studies were performed to compare the power of continuous EFS to a dichotomous EFS24 end point (Data Supplement). All analyses were performed by using SAS v9.2 (SAS Institute, Cary, NC) and R v2.13.0.
RESULTS

Patient Characteristics
In all, 767 patients with newly diagnosed DLBCL who were treated with rituximab and anthracycline-based chemotherapy were enrolled onto the SPORE MER from 2002 to 2009 or the NCCTG-N0489 clinical trial from 2006 to 2007. Median age was 63 years (range, 18 to 92 years) and 53% were male (Table 1) . At a median follow-up of 60 months (range, 8 to 116 months), 299 patients (39%) had an event and 210 patients (27%) had died. Kaplan-Meier estimates for the percentage of patients achieving EFS12 and EFS24 was 77% (95% CI, 74% to 80%) and 71% (95% CI, 67% to 74%), respectively.
Description of Events
An event decomposition was performed to elucidate the risk of relapse compared with other types of events, such as treatment-related death, relapse with indolent non-Hodgkin lymphoma, and death as a result of other causes. At the time of diagnosis, the vast majority of future events were a result of DLBCL relapse ( Fig 1A) with a 5-year risk of relapse of 30% (95% CI, 26% to 33%). Future risk of other event types at the time of diagnosis was low, with 5-year risks no greater than 5% for other event types, including indolent non-Hodgkin lymphoma relapse. Examination of the relapse risk at diagnosis shows that 70% of DLBCL relapses occur within the first year from diagnosis (1-year risk, 21%; 95% CI, 18% to 24%) with a continued declining relapse rate as the time from diagnosis increased. Thus, once a patient completed therapy and achieved EFS12, the risk of future relapse in the following 5 years (Fig 1B) dropped to only 13% (95% CI, 9% to 17%). In patients achieving EFS24, the risk of future DLBCL relapse in the following 5 years improved to 8% (95% CI, 5% to 12%), which was the same as the risk of death as a result of unrelated causes (8%; 95% EFS24 in DLBCL www.jco.org CI, 4% to 12%; Fig 1C) . Achieving additional event-free time from diagnosis resulted in only small gains in future DLBCL relapse risk (Data Supplement).
Comparison of Study Group Survival to That of the General Population
At diagnosis, patients had a significantly decreased survival compared with the age-and sex-matched general population, with an SMR of 2.88 (95% CI, 2.51 to 3.30; P Ͻ .001; Fig 2A) . Survival improved as patients remained in a disease-free state, with patients achieving EFS12 having a subsequent SMR of 1.40 (95% CI, 1.10 to 1.76; P ϭ .0038; Fig 2B) ; the SMR was no longer significant when patients achieved EFS24 (SMR, 1.18; 95% CI, 0.89 to 1.57; P ϭ .25; Fig 2C) . Similar results were seen in cause of death patterns (Fig 3) , with little future lymphoma-related mortality in patients achieving EFS12 ( Fig  3B) or EFS24 (Fig 3C) . In contrast, most patients with an event in the first 12 or 24 months died as a result of lymphoma (Data Supplement). In a sensitivity analysis, results were similar when using a progressionfree definition in which consolidative re-treatment was not considered an event (Data Supplement).
Replication of Survival Results
To replicate the survival findings, an external validation data set of 820 patients with newly diagnosed DLBCL who were treated with rituximab and anthracycline-based chemotherapy was assembled consisting of patients from the GELA LNH05-1B, LNH03-1B, LNH03-2B, LNH03-3B, LNH03-6B and LNH03-7B clinical trials and a hospital-based registry in Lyon, France. Event decomposition and cause of death data were not available. Median age was 62 years (range, 18 to 93 years) and 55% were male (Table  1) . At a median follow-up of 42 months (range, 1 to 129 months), 290 patients (32%) had an event and 221 (24%) had died. KaplanMeier estimates for achieving EFS12 and EFS24 were 80% (95% CI, 77% to 83%) and 73% (95% CI, 70% to 76%), respectively. Results similar to those in the US data set were observed for patient survival when compared with age-and sex-matched survival in the French population. French patients had a larger survival deficit than the US patients at diagnosis (SMR, 4.99; 95% CI, 4.34 to 5.75; P Ͻ .001; Fig 4A) but showed improvement in survival as the duration of the disease-free period increased (EFS12 SMR, 2.06; 95% CI, 1.57 to 2.70; P Ͻ .001; Fig 4B) . As seen in the US data set, there was no significant difference in subsequent survival compared with that for the general population in patients who were disease-free at 24 months (SMR, 1.09; 95% CI, 0.69 to 1.74; P ϭ .71; Fig 4C) .
Additional Analyses in the Pooled Data Sets
To increase power, we next pooled the US and French data sets. In the pooled data, survival after a relapse, re-treatment, or progression event (RRPE) was poor, with a median OS of 13 months (95% CI, 10 to 16 months) after an event other than death. Patients with an RRPE within 1 year from diagnosis had inferior survival (median OS, 8 months; 95% CI, 7 to 10 months) compared with patients with an RRPE between 12 and 24 months (median OS, 28 months; 95% CI, 15 to 50 months) or patients with an RRPE after 24 months (median OS, 36 months; 95% CI, 29 to 55 months; P Ͻ .001). However, 5-year survival rates were similar across the three groups (Data Supplement); additional follow-up on these cohorts of patients will be needed to determine whether there is superior long-term survival for late-relapsing patients. Pretreatment prognostic factors showed an influence on survival, with high-risk subgroups having greater SMR than low-risk subgroups (Fig 5A) , and demonstrated continued impact on post-therapy prognosis for patients achieving EFS12 (Fig 5B) . The only subgroup that did not show a significantly reduced survival compared with the age-and sex-matched general population was in patients achieving EFS12 with stage I to II disease (US SMR, 1.08; 95% CI, 0.71 to 1.59; P ϭ .76; French SMR, 1.35; 95% CI, 0.64 to 2.48; P ϭ .43). Pretreatment prognostic factors no longer identified any patient subgroups with reduced survival once patients achieved EFS24 (Fig 5C) .
In sensitivity analyses, excluding primary mediastinal B-cell lymphoma and GELA patients who received rituximab plus doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) and consolidation with autologous stem-cell transplantation did not significantly change results (data not shown). 
Simulation Study of EFS24 and Continuous EFS
Simulated clinical trials were performed to compare the power of EFS24 and continuous EFS to detect a difference in the DLBCL relapse rate of treatment arms in the presence of a competing risk of unrelated death (Data Supplement). Two primary effect models were assumed: one in which the treatment improved the risk of relapse only in the first year following diagnosis (ie, 12 months [12M] ) and one in which the treatment improved the risk of relapse during the entire course of follow-up (all follow-up
[ALLFU]; Data Supplement). Each simulated trial had an enrollment of 400 patients (200 in each arm) with an enrollment period of 3 years and a varied follow-up period of 24 to 60 months (median follow -up, 3.5 to 6.5 years) . Under the 12M model, in which improvement is limited to the first 12 months when the relapse rate is highest, EFS24 (average power of 76% to detect a 50% reduction in DLBCL relapse between arms) was slightly more powerful than continuous EFS (average power of 69%; Data Supplement). Under the ALLFU model, continuous EFS (average power of 95% to detect a 50% reduction in DLBCL relapse between arms) was slightly more powerful than EFS24 (average power of 91%). The models simulated were selected to be at the extreme ends of potential treatment effects. It is likely that the effect measured in future trials will lie somewhere in between, suggesting that there is comparable power between the two end points. Of note, the power for continuous EFS decreased with additional follow-up time under the 12M effect model and remained relatively consistent under the ALLFU effect model.
DISCUSSION
This study demonstrates that patients with DLBCL treated with standard immunochemotherapy who remain event-free 2 years after diagnosis have excellent long-term outcome with little lymphomarelated mortality in the follow-up period observed in this study. In other words, patients who have achieved EFS24 have subsequent survival comparable to that of the age-and sex-matched general population (ie, a normal life expectancy).
The strengths of the study include the large series of prospectively enrolled patients treated with immunochemotherapy, replication in an independent data set, and patients enrolled onto both registry and trial-based studies from the United States and Europe. This is one of the largest series of patients with DLBCL studied for outcome in the immunochemotherapy era and should have excellent generalizability. The major limitations of this analysis are the under-representation of very elderly patients (older than age 85 years) in our cohort and the lack of long-term (ie, Ͼ 10 years) follow-up since the immunochemotherapy era began in the early 2000s, and our study includes patients prospectively enrolled from the start of this treatment period. 27 In addition, these findings were in patients treated with anthracyclinebased immunochemotherapy regimens, and extrapolation of results to other treatments would be speculative. We also did not assess the impact of management after relapse, which was beyond the scope of this study. It is important to note, as well as communicate to patients, that achieving EFS24 does not establish cure, since approximately 8% of patients event-free at 24 months had a subsequent relapse of DLBCL in the US data set. However; for the roughly 70% of newly diagnosed patients achieving EFS24, as well as perhaps stage I to II patients achieving EFS12, this does mean that the patient now has an OS from that point forward that is equivalent to that of the general non-DLBCL population. In other words, these patients now have a normal life expectancy, and they are now also at greater risk of dying from causes other than their DLBCL. For most patient groups, there is still a reduced survival in patients achieving the EFS12 end point; most of this added mortality in our series was from lymphoma resulting in death (results not shown). Importantly, these survival deficits appear to be resolved in patients once they achieve EFS24. Further follow-up will be needed to look for potential effects of long-term treatment on survival.
These results have important implications in planning new prospective clinical trials for DLBCL, and they support the use of EFS24 as the primary end point. Analysis of DLBCL can be challenging in that the majority of patients can be cured by their initial therapy, and the validity of time-to-event end points such as EFS is influenced by causes other than the intended element being studied (ie, DLBCL relapse/progression). Event decomposition in the US data shows that once patients achieve 24 months of follow-up, at least 50% of any future events will be deaths unrelated to DLBCL from patients in remission. Thus, in contrast to the general rule of thumb "the more follow-up the better," observing patients with DLBCL beyond 24 months for relapse provides little benefit, confirmed by our simulation studies. In addition, examination of the EFS curves in the 4 and MabThera International Trial (MiNT) group 6 trials shows that the separation of outcome between arms occurs within 24 months on each study. Given that the vast majority of DLBCL relapses occur in the first 24 months, any improvement in outcome is expected to manifest in the first 24 months and thus would be captured by the EFS24 end point. EFS24 is also an appealing end point for clinical trial design in DLBCL. It requires only 2 years of follow-up, and studies can be evaluated sooner than when using continuous EFS. It can potentially make trial design more accurate since the standard exponential model used for power calculations is a poor fit for the typical event distribution of DLBCL; the use of EFS24 also avoids potential violations of Cox proportional hazards models. Thus, when the primary goal is comparison of disease-related events, we recommend using EFS24 as the end point for outcome studies or clinical trials of patients with newly diagnosed DLBCL. Additional follow-up beyond 24 months is still needed for assessment of overall survival and to monitor for late complications such as progressive multifocal leukoencephalopathy or cardiomyopathy.
These data provide important insight into developing informed clinical strategies for post-therapy surveillance and management. The excellent outcome of patients achieving EFS24, and perhaps patients with low-stage disease who achieve EFS12, call into question the utility of routine surveillance imaging for patients in remission beyond these time points. Investigation of strategies involving prolonged postremission therapy will also benefit from a more precise understanding of expected outcomes from key landmark time points. Clinical risk prediction models for achieving EFS24 should be developed to identify patients at high risk of early relapse to help prioritize patients for clinical trials or alternative management strategies. Finally, these results will help physicians and patients develop a survivorship care plan, which will also need to address nonlymphoma health issues and potential late effects of therapy that are perhaps more likely to have an impact on life expectancy.
In conclusion, patients with newly diagnosed DLBCL who were treated with immunochemotherapy who are event-free 24 months after diagnosis have excellent outcome, with an OS equivalent to that of the age-and sex-matched general population in both US and French data sets. Consideration of EFS24 as an end point in clinical trials and biologic studies of newly diagnosed DLBCL is warranted. 
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